European Journal of Clinical Pharmacology

, Volume 75, Issue 2, pp 285–286 | Cite as

How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?

  • Tomáš Bolek
  • Matej SamošEmail author
  • Ingrid Škorňová
  • Lucia Stančiaková
  • Barbora Korpallová
  • Peter Galajda
  • Ján Staško
  • Peter Kubisz
  • Marián Mokán
Letter to the Editor

To the Editor:

Long-term oral anticoagulation is recommended to prevent stroke and systemic embolism in patients with atrial fibrillation (AF) [1]. Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as the preferred choice in these patients [2].However, published data has recently demonstrated that dabigatran-PPI interaction significantly reduces dabigatran plasma levels [3, 4], most probably mediated through the effect on gastric pH [5]. This implies that dabigatran would not be highly soluble also among post-total gastrectomy patients, as they have no gastric acid secretion. Nevertheless, there are no data about post-total gastrectomy patients with non-valvular atrial fibrillation treated with dabigatran.

A 68-year-old post-total gastrectomy patient due to the diffuse large B cell lymphoma, in complete remission, and with permanent AF, was admitted to the Department of Internal Medicine I. He had been taking 150 mg of dabigatran etexilatetherapy twice daily before...



The authors would like to thank Mr. Paul McCullough for proofreading.


This study was supported by project APVV (Slovak Research and Development Agency) 16-0020 and by research project UK/386/2018 of Comenius University in Bratislava.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval and inform consent

This research was done according to ethical standards and was approved by the local ethical committee (Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava). The patient agreed to participate in the research and signed an informed consent for study participation.

Supplementary material

228_2018_2571_MOESM1_ESM.docx (94 kb)
ESM 1 (DOCX 91 kb)
228_2018_2571_MOESM2_ESM.docx (85 kb)
ESM 2 (DOCX 82 kb)


  1. 1.
    Kirchhof P, Benussi S, Kotecha D et al (2016) ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962CrossRefGoogle Scholar
  2. 2.
    Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393CrossRefGoogle Scholar
  3. 3.
    Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J, Galajda P, Kubisz P, Mokáň M (2017) The Impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther.
  4. 4.
    Kuwayama T, Osanai H, Ajioka M, Tokuda K, Ohashi H, Tobe A, Yoshida T, Masutomi T, Kambara T, Inoue Y, Nakashima Y, Asano H, Sakai K (2017) Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm 33:619–623CrossRefGoogle Scholar
  5. 5.
    Ollier E, Hodin S, Basset T, Accassat S, Bertoletti L, Mismetti P, Delavenne X (2015) In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol 29:604–614CrossRefGoogle Scholar
  6. 6.
    Stangier J, Eriksson BI, Dahl OE et al (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45:555–563CrossRefGoogle Scholar
  7. 7.
    Kreutz R (2014) Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xainhibitor. Curr Clin Pharmacol 9:75–83CrossRefGoogle Scholar
  8. 8.
    Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81CrossRefGoogle Scholar
  9. 9.
    Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743–753CrossRefGoogle Scholar
  10. 10.
    Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y (2018) The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thromb Res 163:190–195CrossRefGoogle Scholar
  11. 11.
    Reilly PA, Lehr T, Haertter S et al (2014) RE-LY investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol 63:321–328CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Internal Medicine I, Jessenius Faculty of Medicine in MartinComenius University in BratislavaMartinSlovak Republic
  2. 2.National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in MartinComenius University in BratislavaMartinSlovak Republic

Personalised recommendations